Pain reduction at the @-week endpoint was significant in BTX-A group ( p < @ ) ; VAS scores at endpoint LOCF relative to baseline for BTX-A group showed a decrease of @ compared with a decrease of @ for placebo , also there was a significant decrease in the number of acute medications and an increase in QoL functioning scale .